Status Migrainosus: When a Migraine Lasts Over 72 Hours

Status migrainosus is a migraine attack that refuses to end, lasting at least 72 continuous hours despite treatment. The International Classification of Headache Disorders defines it as a debilitating migraine that crosses that three-day threshold, though researchers have pointed out this cutoff was drawn from tradition rather than hard evidence.¹ Because the pain is relentless and typically resistant to the medications that work for ordinary migraines, status migrainosus often drives people to emergency departments and sometimes requires inpatient admission.

The 72-Hour Rule and Why It Is Contested

The formal diagnostic criterion is straightforward: a migraine attack persisting for more than 72 hours, with pain that is either continuous or interrupted only by brief periods of relief lasting under 12 hours, usually related to sleep or medication.² The problem is that nobody chose 72 hours because a study proved something changes biologically at that mark. The threshold was carried forward through successive editions of the headache classification system, grounded more in clinical convention than in data showing that a 71-hour migraine is fundamentally different from a 73-hour one.³

This matters because clinicians sometimes hesitate to escalate treatment until the official criterion is met, and patients sometimes wait too long to seek help because they think a two-day migraine “isn’t bad enough.” In practice, any migraine that has not responded to appropriate treatment and keeps grinding past a day or two should prompt a conversation with a doctor about whether more aggressive intervention is warranted. The 72-hour label is useful for classification and research, but it should not be treated as a gate that must open before you take the situation seriously.

What Happens in the Brain During a Prolonged Attack

Ordinary migraines involve activation of a network of pain-sensing nerves around the brain’s protective membranes, called the trigeminovascular system. In a typical attack, these nerves fire, blood vessels in the meninges dilate, and you feel the characteristic throbbing. If the attack is stopped early enough, the system quiets down. In status migrainosus, the pain signals keep firing long enough that the system starts to amplify itself.

The first stage involves the peripheral nerve endings around the meninges becoming increasingly sensitive, which intensifies the throbbing. As that sensitization persists, it spreads inward to neurons in the brainstem that receive signals from both the meninges and the skin of the face and scalp. This is what produces allodynia, where normally harmless touch on the head starts to feel painful. Someone in the middle of a prolonged migraine may find it excruciating to brush their hair, wear glasses, or rest their head on a pillow.⁴

If the attack drags on further, the sensitization can climb to third-order neurons in the thalamus, which process sensory input from the entire body. At that point, allodynia spreads beyond the head: even touching an arm or leg can feel unpleasant. Meanwhile, the brain’s built-in pain-dampening systems start to fail. Research has shown that repeated activation of these pain pathways not only ramps up nerve excitability but also weakens the inhibitory controls that normally keep pain signals in check.⁵ The result is a feedback loop: more pain begets more sensitization, which begets more pain. This is a key reason why status migrainosus is so hard to break once it is established, and why early, aggressive treatment is the preferred strategy.

When to Go to the Emergency Room

A migraine that simply will not stop is miserable, but the more urgent concern in an emergency department is making sure the headache is not a sign of something dangerous. Thunderclap onset, fever, neurological symptoms like weakness or confusion, and a first-ever headache in someone over 50 are all red flags that shift the priority from pain relief to ruling out conditions like subarachnoid hemorrhage, meningitis, or stroke.⁶ If you have a known migraine history and the headache feels like your usual pattern, just longer and worse, the clinical picture is different from someone experiencing an entirely new type of head pain.

Some emergency departments have started using structured triage scores to quickly sort headache patients. One protocol, for instance, assigns points for features like vomiting, pain lasting more than 72 hours, pain intensity above seven out of ten, and failure of home medications. Patients who score high enough get moved to a quiet, dimly lit observation area with a target of receiving treatment within 30 minutes.⁷ The emphasis on environment is not a nice-to-have: light and noise sensitivity are hallmarks of migraine, and a loud, bright ER waiting room can actively worsen the attack.

You should seek emergency care if your migraine is accompanied by any neurological symptoms you do not normally experience, if you develop a fever, if the pain peaks instantly rather than building gradually, or if you cannot keep fluids down and are becoming dehydrated. A migraine that has lasted three or more days and is not responding to your usual medications is also a reasonable reason to go, even without those red flags.

How Emergency Departments Treat It

The mainstay of emergency treatment for status migrainosus is intravenous medication, because most patients have already failed oral drugs at home, and many are vomiting too much for oral medications to be absorbed. The evidence favors a few specific approaches.

Metoclopramide, an anti-nausea drug that also has direct migraine-relieving properties, is among the best-studied options. In a randomized trial comparing intravenous metoclopramide, ketorolac (a strong anti-inflammatory), and valproate (an anticonvulsant), metoclopramide produced the largest pain improvement and had the lowest rate of patients needing rescue medication at roughly a third, compared with about half for ketorolac and about two-thirds for valproate.⁸ Valproate, despite being commonly used, performed worst on nearly every measure in that trial. Ketorolac landed in the middle. These results have led many emergency physicians to reach for metoclopramide first, often combined with diphenhydramine to prevent the restlessness that metoclopramide can cause.

Other commonly used agents include prochlorperazine (another anti-nausea drug from the same class as metoclopramide), sumatriptan given by injection, and magnesium sulfate. The choice often depends on what the patient has already tried, what their contraindications are, and clinician preference. Opioids are generally avoided because they tend to worsen migraine in the long run and increase the risk of the headache coming back.

Corticosteroids and Preventing Rebound

One of the most frustrating aspects of status migrainosus is the tendency for the headache to roar back within a day or two of emergency treatment. This is where corticosteroids come in. A single dose of intravenous dexamethasone added to standard acute treatment roughly halved the rate of severe recurrent headache in one trial, dropping it from about 45% in the placebo group to about 18%.⁹

A meta-analysis pooling seven trials confirmed the benefit, finding that dexamethasone reduced the chance of headache recurrence within 24 to 72 hours by about a quarter compared with placebo. The estimated number needed to treat was nine, meaning roughly one in every nine patients given dexamethasone was spared a recurrence that would have happened otherwise.¹⁰ Dexamethasone does not seem to help much with the immediate pain, so it is used alongside a primary pain-relieving drug rather than as a standalone treatment. Its value is in reducing the odds that you end up back in the ER two days later.

Nerve Blocks

When medications alone are not cutting it, procedural options can help. The most common is a greater occipital nerve block, which involves injecting a local anesthetic near a nerve at the back of the head. This is a quick, office- or bedside-level procedure that takes only a few minutes. The rationale is that the greater occipital nerve feeds into the same brainstem pain circuits that drive migraine, so numbing it can interrupt the cycle of sensitization.

In pediatric patients presenting to the emergency department with status migrainosus, greater occipital nerve blocks produced meaningful improvement in the majority of cases, with the benefit still holding at a seven-day follow-up.¹¹ The procedure is attractive because it has a low side-effect profile and can be done alongside IV medications. For adults, nerve blocks are similarly used as an adjunct, especially when the attack has not responded to multiple rounds of intravenous drugs. Sphenopalatine ganglion blocks, performed through the nose with a thin applicator, are another option that some headache specialists employ, though the evidence base for status migrainosus specifically is thinner.

Treatment in Children and Adolescents

Status migrainosus is not limited to adults. Children and teenagers can experience it too, and the treatment landscape looks somewhat different because many of the standard adult medications have less pediatric safety data. The approach generally starts the same way: intravenous fluids, anti-nausea medications, and ketorolac or a similar anti-inflammatory. But when the attack proves refractory, hospitals sometimes turn to continuous intravenous infusions, which means the child is admitted and receives a slow drip of medication over hours or days.

A comparison of intravenous lidocaine and intravenous valproate infusions in hospitalized children with status migrainosus found lidocaine to be considerably faster at controlling pain. The median time to being pain-free was roughly 12 hours with lidocaine versus more than 43 hours with valproate. At discharge, about two-thirds of the lidocaine group were pain-free, compared with fewer than half of the valproate group. Lidocaine also had far fewer side effects and infusion interruptions.¹² Lidocaine infusion requires cardiac monitoring because of its effects on heart rhythm, so it is not something done casually, but the results suggest it may be a better choice than valproate for children who need that level of escalation.

Pregnancy and Status Migrainosus

Pregnancy complicates the picture because many standard migraine medications are off-limits or carry uncertain safety profiles. Triptans, the workhorse of acute migraine treatment outside pregnancy, were long avoided due to theoretical concerns, though more recent data suggest their risk may be lower than previously assumed.¹³ Nonetheless, most pregnant patients presenting with status migrainosus are treated with a narrower toolkit.

In a retrospective look at pregnant women presenting to acute care with migraine, nearly half met criteria for status migrainosus. The most frequently used medications were metoclopramide and acetaminophen, and metoclopramide was typically given with diphenhydramine. Acetaminophen was the most common first-line choice. About a third of patients also received butalbital-containing medications, and roughly 30% received opioids as second- or third-line options.¹⁴ The reliance on opioids is notable and somewhat concerning, given the general push to minimize opioid use for migraine, but it reflects the limited alternatives available during pregnancy.

Peripheral nerve blocks and noninvasive neurostimulation devices are gaining interest as safer procedural options for pregnant patients, since they avoid systemic drug exposure almost entirely.¹⁵ A greater occipital nerve block, for example, delivers local anesthetic to a small area and does not circulate through the bloodstream in meaningful amounts. For pregnant patients with status migrainosus, these interventions may fill a gap where medication options are limited.

Who Ends Up Staying Longer in the Hospital

Most people with status migrainosus who are admitted to a hospital are discharged within a couple of days once the cycle is broken. But some patients end up with prolonged stays, and the predictors of that are revealing. A large analysis found that female sex, mood disorders such as depression and anxiety, obesity, opioid misuse, and certain chronic medical conditions like heart failure and kidney disease were all independently associated with longer hospital stays.¹⁶

The mood disorder finding is not surprising to headache specialists. Depression and anxiety are well-established comorbidities of migraine in general, and they appear to make attacks harder to treat, possibly because overlapping neurotransmitter systems are involved. Chronic stress can lower the threshold for central sensitization, the same amplification process that drives status migrainosus in the first place. The opioid misuse connection is also meaningful: patients who have been overusing opioids for headache or other pain may have rebound headache layered on top of the migraine, making the entire picture harder to untangle.

What Happens After Discharge

Breaking the acute attack is only half the battle. Someone who has experienced status migrainosus is, by definition, someone whose migraines can escalate to a dangerous degree, and the goal after discharge is to make sure it does not keep happening. In a retrospective analysis of hospitalized status migrainosus patients, roughly nine out of ten were started on or had adjustments made to preventive migraine therapy before leaving the hospital.¹⁷

Preventive therapy is medication taken daily (or, with newer biologics, monthly) to reduce the frequency and severity of migraines before they start. The specific choices range from older drugs originally developed for blood pressure or seizures to newer monoclonal antibodies that target calcitonin gene-related peptide (CGRP), a molecule heavily involved in migraine signaling. The decision about which preventive to use depends on the patient’s other medical conditions, medication tolerance, and how frequent their attacks are.

Just as important as medication is addressing the factors that contributed to the episode. Were acute medications being overused, potentially feeding a rebound cycle? Was a preventive medication discontinued or never started? Were stress, sleep disruption, or hormonal changes obvious triggers? A post-discharge headache clinic follow-up is the place to sort this out, and it should happen sooner rather than later. Waiting two months for a neurology appointment after a hospitalization for status migrainosus is a common frustration, and some headache centers have started offering expedited post-discharge visits to close that gap.

The Medication Overuse Trap

One of the trickiest situations arises when status migrainosus overlaps with medication overuse headache. If someone has been taking acute pain relievers, whether over-the-counter analgesics, triptans, or opioids, too frequently, the brain adapts in a way that actually lowers the pain threshold. The medication that was supposed to help starts perpetuating the headache cycle. When this background of medication overuse collides with a prolonged migraine attack, the two become nearly impossible to separate clinically.

The standard recommendation is to withdraw the overused medication while simultaneously starting or optimizing preventive treatment. In practice, this is extremely difficult to do during an acute status migrainosus episode because the patient is in severe pain and the withdrawal itself can temporarily worsen headaches. Most headache specialists will focus on breaking the acute attack first and then address the overuse pattern in a planned, supported way after discharge. Recognizing the overlap is important, though, because if the overuse issue goes unaddressed, the patient is highly likely to end up right back in the emergency department.

Noninvasive Neurostimulation Devices

Several devices cleared for migraine treatment deliver mild electrical or magnetic stimulation to nerves involved in the migraine pathway, and they are increasingly being explored for status migrainosus. Vagus nerve stimulators applied to the neck, transcranial magnetic stimulation devices held against the back of the head, and supraorbital stimulation bands worn across the forehead all fall into this category. Their appeal is obvious: they have minimal systemic side effects, can be used alongside medications, and are safe in populations where drugs are limited, such as pregnant patients.¹⁸

The evidence for these devices in the specific context of status migrainosus, as opposed to ordinary migraine attacks, is still limited. Most of the regulatory trials studied single attacks of moderate severity, not multi-day crises. Clinicians who use them for status migrainosus are often extrapolating from the general migraine data and from a common-sense view that a low-risk intervention is worth trying when other options have failed or are contraindicated. As more headache centers incorporate these devices into their emergency and inpatient protocols, clearer data on their role in prolonged refractory attacks should emerge.